AbbVie Q2 Earnings Preview: Can Immunology Drugs Offset Humira Decline?
AbbVie (ABBV) is set to report Q2 2025 earnings on July 31, with analysts focusing on Skyrizi and Rinvoq sales to compensate for declining Humira revenue.
Key Numbers
AbbVie (ABBV) is set to report its second-quarter 2025 earnings on July 31, with investors closely watching the performance of its immunology portfolio. The company's newer drugs, Skyrizi and Rinvoq, are expected to offset the continued decline of Humira, which faces biosimilar competition.
Key Financial Metrics
AbbVie has not yet released Q2 results, but consensus estimates are:
| Metric | Q2 2025 (Est.) | Q2 2024 (Actual) |
|---|---|---|
| Revenue | TBD | $14.4B |
| EPS | TBD | $2.65 |
Highlights from the Report
No official report yet, but key areas of focus include:
- Skyrizi and Rinvoq sales growth.
- Humira revenue decline rate.
- Pipeline updates.
Future Guidance
Management is expected to provide full-year 2025 guidance, particularly on biosimilar impact.
Stock Impact
Strong immunology sales could support ABBV stock, while any miss may pressure shares.
What This Means for Investors
AbbVie is transitioning from Humira reliance to next-generation drugs. Investors will gauge the pace of Skyrizi and Rinvoq adoption to assess revenue sustainability.
Frequently Asked Questions
Found this useful? Share it